Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 13/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 8/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 8/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 8/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 8/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369419 | 0.83 | MAP3K7 (0.37) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL348680 | 0.82 | ALDH1A1 (0.42) | PRKAA2ALDH1A1SMN1; SMN2HRH3ACKR3 | |
| SCHEMBL348333 | 0.78 | TP53 (0.41) | ALDH1A1SMN1; SMN2HRH3ACKR3KMT2A | |
| SCHEMBL348445 | 0.77 | KMT2A (0.43) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL348679 | 0.72 | HRH3 (0.47) | ALDH1A1SMN1; SMN2HRH3ACKR3KMT2A | |
| SCHEMBL348818 | 0.69 | ACKR3 (0.51) | ALDH1A1HRH3ACKR3 | |
| SCHEMBL347641 | 0.69 | HRH3 (0.42) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL346910 | 0.68 | ALDH1A1 (0.41) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL347099 | 0.68 | PRKAA2 (0.44) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL13458584 | 0.68 | HRH3 (0.42) | SMN1; SMN2HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | PRKAA2 4031/4885PRKAB2 4576/4885PRKAG1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.